NCT02124850View on ClinicalTrials.gov

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

August 11, 2016

Study Completion Date

October 31, 2016

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Motolimod

DRUG

Cetuximab

DRUG

Nivolumab

Trial Locations (1)

15232

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY